Amfepramone - direct healthcare professional communication (DHPC)

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Amfepramone-containing medicines will no longer be available on the EU market, as marketing authorisations will be revoked

Key facts

• Active substance:
  amfepramone
• Therapeutic area (MeSH):
  Obesity
• Procedure number:
  EMEA/H/A-31/1501
• Regulatory outcome:
  Revocation
• DHPC type:
  Referral - Article 31
• Human ATC codes:
  A08AA03
• Dissemination date:
  08/02/2023
• Related medicines:
  • Regenon
  • Tenuate Retard
  • Amfepramon-Hormosan
  • Regenon Retard